跳至主要内容
临床试验/ISRCTN36766542
ISRCTN36766542已完成未知

ipodystrophy in human immunodeficiency virus-infected patients: a randomised, open-label study with rosiglitazone and metformin

GlaxoSmithKline (The Netherlands)0 个研究点目标入组 39 人开始时间: 2005年6月10日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
39

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • HIV-Ribonucleic Acid (RNA) values less than 10,000 copies/ml, the presence of lipodystrophy, and treatment with Highly Active Anti-Retroviral Therapy (HAART) for at least 18 months with no changes in the treatment regimen during six months prior to inclusion.

排除标准

  • 1. The presence of opportunistic infectious disease or malignancies, renal-, thyroid- and/or liver disease
  • 2. Body Mass Index (BMI) more than 30 kg/m^2
  • 3. Fasting plasma glucose more than 7 mmol/l
  • 4. Triglycerides more than 10 mmol/l and/or total cholesterol more than 8 mmol/l
  • 5. Alcohol intake more than three units (36 g) per day

研究者

发起方
GlaxoSmithKline (The Netherlands)

相似试验